Cabio Biotech (Wuhan) Co., Ltd.

SHSE:688089 Stock Report

Market Cap: CN¥4.2b

Cabio Biotech (Wuhan) Future Growth

Future criteria checks 3/6

Cabio Biotech (Wuhan) is forecast to grow earnings and revenue by 20.7% and 18.6% per annum respectively. EPS is expected to grow by 20.6% per annum. Return on equity is forecast to be 12.1% in 3 years.

Key information

20.7%

Earnings growth rate

20.6%

EPS growth rate

Chemicals earnings growth35.3%
Revenue growth rate18.6%
Future return on equity12.1%
Analyst coverage

Low

Last updated31 Mar 2025

Recent future growth updates

Recent updates

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Mar 07
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) 26% Dip In Price Shows Sentiment Is Matching Earnings

Jan 12
Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) 26% Dip In Price Shows Sentiment Is Matching Earnings

We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Nov 04
We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Oct 28
Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

Oct 01
Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Aug 06
There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Jun 07
Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

May 06
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

May 03
Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21
The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Earnings and Revenue Growth Forecasts

SHSE:688089 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,010241N/A2462
12/31/2026791184N/A1884
12/31/2025671153N/A1623
12/31/2024556124-39173N/A
9/30/2024506115-89150N/A
6/30/2024506124-84173N/A
3/31/2024473101-169118N/A
12/31/202344491-22969N/A
9/30/202348547-178118N/A
6/30/202346149-150106N/A
3/31/202344655-126107N/A
12/31/202243364-73176N/A
9/30/2022374105-104133N/A
6/30/2022359111-96153N/A
3/31/2022348118-66177N/A
12/31/2021351129-70103N/A
9/30/2021337121-3484N/A
6/30/20213361272498N/A
3/31/20213471393678N/A
12/31/2020323131113146N/A
9/30/2020317132152174N/A
6/30/2020315126147161N/A
3/31/2020301121145165N/A
12/31/2019312118109132N/A
9/30/201931812889119N/A
12/31/20182869794106N/A
12/31/201722966N/A101N/A
12/31/201619047N/A63N/A
12/31/201518120N/A45N/A
12/31/201418738N/A46N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688089's forecast earnings growth (20.7% per year) is above the savings rate (2.7%).

Earnings vs Market: 688089's earnings (20.7% per year) are forecast to grow slower than the CN market (23.3% per year).

High Growth Earnings: 688089's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688089's revenue (18.6% per year) is forecast to grow faster than the CN market (12.6% per year).

High Growth Revenue: 688089's revenue (18.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688089's Return on Equity is forecast to be low in 3 years time (12.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/28 11:38
End of Day Share Price 2025/04/28 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cabio Biotech (Wuhan) Co., Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wendan WangChina International Capital Corporation Limited
Yunpeng FangChina International Capital Corporation Limited
Yifan DuCitic Securities Co., Ltd.